glp 1 7 36 amide GLP-1 (7-37, 7-36, amide, free NT) monoclonal antibody (10) (biotin conjugate) Glucagon-like Peptide-1 (GLP-1) (7-36) /

Description

Also to be mentioned are rare but serious side effects such as acute pancreatitis, gallbladder disease, and a possible risk of medullary thyroid carcinoma []

The combination of recent surgery, altered anatomy, and GLP-1 therapy demands close monitoring for nausea, vomiting, or other GI symptoms in the first 4 to 6 weeks post-op

Subgroup analysis of phase 3 studies of dulaglutide in Japanese patients with type 2 diabetes

Additionally, these medications enhance glucose-dependent insulin secretion from pancreatic beta cells whilst suppressing inappropriate glucagon release, thereby improving glycaemic control in individuals with type 2 diabetes

Research shows modest, incremental HbA1c reductions (typically 0.30.8%) when adding a DPP-4 inhibitor to a GLP-1 drug, but many patients achieve superior glucose control by simply increasing their GLP-1 dose or switching to a dual-agonist like tirzepatide